Amgen Inc (AMGN) - Stock Report

The latest evidence is mixed in exactly the way a biopharma transition story should be tested. In Q1 2026, revenue rose 6% to $8.6 bn and product sales grew 4%, with 9% volume growth partly offset by 2% lower net selling price and lower inventory levels; FY2026 guidance calls for revenue of $37.1 bn to $38.5 bn, reported diluted EPS of $15.62 to $17.10, adjusted diluted EPS of $21.70 to $23.10, capex of about $2.6 bn, and buybacks not to exceed $3.0 bn. Reported diluted EPS was $3.34, adjusted diluted EPS was $5.15, reported operating margin improved to 32.4%, and adjusted operating margin slipped to 45.3%. The replacement bridge is visible but incomplete: Repatha rose 34%, EVENITY 27%, TEPEZZA 29%, BLINCYTO 12%, and IMDELLTRA more than tripled, while Prolia fell 34%, XGEVA fell 27%, and Enbrel fell 37%. Q1 company-reported free cash flow was $1.5 bn after $0.7 bn of capex, covering $1.4 bn of dividends with only about $0.1 bn of excess for the quarter and no buybacks; cash was $12.0 bn against $57.3 bn of debt.

Amgen discovers, develops, manufactures and commercializes human therapeutics. It reports one operating segment, but economically it is a portfolio of branded therapies, led by biologics and including small-molecule products such as Otezla. The company sells through a concentrated pharmaceutical distribution channel, with McKesson, Cencora and Cardinal Health representing 77% of 2025 worldwide gross revenues.

The value stack is not just holding drug rights. Amgen combines research, clinical development, biologics manufacturing, regulatory execution, payer access and lifecycle management. That stack supports high adjusted margins when mature therapies are protected, but it also creates a permanent replacement requirement because biologics face biosimilars, small molecules face generics, and U.S. pricing pressure can reduce retained economics even when volumes grow.

Management is trying to keep the cash engine broad enough to absorb a product cliff. The priorities are Repatha expansion, Horizon rare-disease integration, oncology launches such as IMDELLTRA, TEZSPIRE growth, and MariTide. These assets must do more than add revenue; they must replace high-margin mature-product profit while Amgen still funds R&D, dividends, debt service and manufacturing investment.